09969

InnoCare Pharma

9.50

-0.02-0.21%

Closed16:08 05/13 HKT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE9.920/9.520

TODAY RANGE9.470-9.980

VOL7.79M

MARKET CAP16.74B

52 WEEK RANGE4.220-10.960

AVG VOL (3M)13.88M

% TURNOVER0.44%

TURNOVER74.77M

P/E (TTM)-35.157

% RANGE5.36%

EPS(TTM)-0.270

P/E(FORWARD)-30.226

P/B2.303

BVPS4.124

DIVIDEND--

P/S21.149

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP14.20B

SHARES OUTSTANDING1.76B

NEXT EARNINGS--

FREE FLOAT1.49B

LOT SIZE1000

EX-DIV DATE--

News

Press Releases

Financial Reports

Profile

Reuters·7h ago
INNOCARE PHARMA Q1 GROSS MARGIN 90.5%
Reuters·04/25 09:34
INNOCARE ANNOUNCES APPROVAL OF ORELABRUTINIB FOR THE FIRST-LINE TREATMENT OF CLL/SLL IN CHINA
Simply Wall St·04/22 23:05
What InnoCare Pharma Limited's (HKG:9969) 26% Share Price Gain Is Not Telling You
Simply Wall St·04/01 22:05
Exploring High Growth Tech Stocks in Asia April 2025
Simply Wall St·03/17 07:17
Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 49% Undervaluation?
Simply Wall St·02/18 22:37
InnoCare Pharma Limited (HKG:9969) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Reuters·02/17 12:55
INNOCARE ANNOUNCES THE APPROVAL OF REGISTRATIONAL PHASE III STUDY OF BCL2 INHIBITOR ICP-248 IN COMBINATION WITH ORELABRUTINIB AS FIRST-LINE THERAPY FOR TREATMENT OF CLL/SLL PATIENTS IN CHINA
Reuters·01/20 10:36
INNOCARE AND KEYMED JOINTLY ANNOUNCE THE LICENSE AGREEMENT WITH PROLIUM FOR CD20XCD3 BISPECIFIC ANTIBODY ICP-B02
Simply Wall St·01/14 01:19
Institutions along with individual investors who hold considerable shares inInnoCare Pharma Limited (HKG:9969) come under pressure; lose 6.2% of holdings value
Simply Wall St·12/18/2024 01:08
Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now
Simply Wall St·11/12/2024 22:22
InnoCare Pharma Third Quarter 2024 Earnings: CN¥0.007 loss per share (vs CN¥0.062 loss in 3Q 2023)
Reuters·11/11/2024 08:35
INNOCARE PHARMA 9M GROSS MARGIN 86%
Simply Wall St·11/03/2024 00:40
InnoCare Pharma (SEHK:9969) Achieves Key Milestone with ICP-488 Phase II Success in Psoriasis Treatment
Simply Wall St·10/21/2024 23:49
Is InnoCare Pharma (HKG:9969) A Risky Investment?
Simply Wall St·09/13/2024 23:05
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Same Industry

Name/Symbol

Change%

Price

InnoCare Pharma

09969

-0.21%

9.500

Shanghai Haohai Biological Technology

06826

-1.48%

23.350

Wuxi Apptec

02359

-0.64%

62.400

Hangzhou Tigermed Consulting

03347

-1.47%

26.900

JOINN Laboratories (China)

06127

+0.10%

9.960

Pharmaron Beijing

03759

-1.45%

13.620

BBI Life Sciences

01035

0.00%

3.490

Frontage Holdings

01521

+4.59%

1.140

Mingyuan Medicare Development

00233

0.00%

0.230

China Health Group

08225

+2.56%

0.160

China Regenerative Medicine International

08572

0.010

China Regenerative Medicine International

08158

0.00%

0.360

Mabpharm

02181

0.00%

0.440

Viva Biotech Holdings

01873

+11.89%

1.600

TOT Biopharm International

01875

0.00%

1.800

Hua Medicine

02552

+1.04%

1.950

MicroPort NeuroScientific

02172

-1.28%

10.800

Alphamab Oncology

09966

+3.13%

6.600

SinoMab BioScience

03681

+1.64%

1.240

Lepu Biopharma

02157

-0.23%

4.270

Jacobio Pharmaceuticals Group

01167

+13.94%

4.250

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.